Financial Performance - The company achieved total operating revenue of RMB 782.65 million in 2024, representing a year-on-year growth of 33.36%[4] - Operating profit increased to RMB 94.50 million, up 44.94% compared to the previous year, while total profit rose to RMB 93.57 million, a 43.15% increase[4] - Net profit attributable to shareholders reached RMB 81.11 million, reflecting an 18.29% growth year-on-year, with a significant increase of 104.11% in net profit after deducting non-recurring gains and losses, totaling RMB 64.47 million[7] Gross Margin and Revenue Composition - The company's gross margin for 2024 was 70.24%, a decrease of approximately 7.65 percentage points from the previous year, primarily due to an increase in the proportion of instrument product revenue[6] - The core business of chromatography fillers and chromatography media generated approximately RMB 451 million in revenue, growing about 10.20% year-on-year[6] Research and Development - Research and development investment amounted to RMB 177 million, a 9.47% increase from the previous year, accounting for 22.61% of total operating revenue[7] Cash Flow and Assets - The net cash flow from operating activities was approximately RMB 132 million, representing a year-on-year growth of about 5.11%[7] - The total assets at the end of the reporting period were RMB 2.31 billion, an increase of 8.67% from the beginning of the period[4] Equity and Investments - The weighted average return on equity increased to 4.74%, up 0.51 percentage points from the previous year[4] - The company acquired a partial stake in Fuli Instruments, which contributed RMB 153.54 million to the consolidated revenue starting from March 2024[8]

证券代码：688690 证券简称：纳微科技 公告编号：2025-003 苏州纳微科技股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 回购方案首次披露日 | 2024/1/31，由公司实际控制人、董事长江必旺博 | | --- | --- | | | 士提议 | | 回购方案实施期限 | 自董事会审议通过后 12 个月内 | | 预计回购金额 | 万元~10,000 万元 5,000 | | 回购价格上限 | 35 元/股 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 实际回购股数 | 306.6622 万股 | | 实际回购股数占总股本比例 | 0.76% | | 实际回购金额 | 6,099.45 万元 | | 实际回购价格区间 | 15.52 元/股~22.18 元/股 | 重要内容提示： 一、 回购审批情况和回购方案内容 （四）本次实施股份回购使用的资金为自有资金 ...

Business Growth Opportunities - The company has significant growth opportunities in the GLP-1 class peptide drug applications, with rapid revenue growth in this area over the past two years [1] - The company is optimizing product performance to enable domestic chromatographic filler replacements without changing purification process conditions [1] - The current focus is primarily on injectable drug formulations, with potential for further market expansion if oral drugs achieve mass production [1] Customer Considerations for Filler Suppliers - For macromolecule customers, key factors include a complete quality management system, reliable production and supply capabilities, and competitive pricing [1] - For small molecule customers, suppliers must provide improved separation and purification processes to meet green production trends and market competition pressures [1] Investor Relations Activities - The company held a meeting with investors on December 25, 2024, to discuss performance, management, product development, market expansion, and team integration [1] - Participants included representatives from Tianfeng Securities, Fullgoal Fund, Soochow Securities, Bank of China, Orient Red, Morgan, and Shenwan Lingxin [1]

证券代码：688690 证券简称：纳微科技 公告编号：2024- 苏州纳微科技股份有限公司 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 本次减持计划实施前，苏州纳微科技股份有限公司（以下简称"公司"）股 东深圳市纳微科技有限公司（以下简称"深圳纳微"）持有公司股份 78,096,992 股，占公司总股本的 19.3398%，其中无限售条件的流通股 78,096,992 股。 上述股份为公司首次公开发行前取得的股份，并已于 2024 年 6 月 24 日起上 市流通。深圳纳微股东分别为 BIWANG JACK JIANG（中文名：江必旺）博士和陈 荣华先生，其中江必旺博士是公司实际控制人、董事长，持有深圳纳微股权比例 为 77.5973%，陈荣华先生持有深圳纳微股权比例为 22.4027%。 082 减持计划的实施结果情况 2024 年 8 月 31 日，公司披露了《苏州纳微科技股份有限公司股东减持股份 计划公告》（公告编号：2024-065），股东 ...

Company Information - Nantong Nawei New Materials Co Ltd was recently established with a registered capital of 100 million yuan [2] - The company is wholly owned by Nawei Technology according to equity penetration data [1] - The legal representative of the new company is Jiang Biwang [2] Business Scope - The company's business scope includes new material technology promotion services [2] - It is involved in bio-based material manufacturing [2] - The company engages in new material technology research and development [2] - Synthetic material sales are part of its business operations [2] Industry Focus - The establishment indicates Nawei Technology's expansion in the new materials sector [2] - The company's focus on bio-based materials aligns with emerging industry trends [2] - The 100 million yuan investment demonstrates significant commitment to material science innovation [2]

证券代码：688690 证券简称：纳微科技 公告编号：2024-081 苏州纳微科技股份有限公司 关于拟设立子公司并购买土地使用权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 苏州纳微科技股份有限公司（以下简称"公司"）拟在南通市如东洋口 港经济开发区设立全资子公司，并以全资子公司的名义使用自筹资金购买土地使 用权，总占地面积约为120亩。 本次拟对外投资设立子公司并购买土地使用权的行为不涉及关联交易， 亦不构成重大资产重组。 特别风险提示：本次拟购买工业用地使用权需要通过公开竞拍方式进 行，土地使用权能否竞得、土地使用权的最终成交价格及取得时间存在不确定 性。 （二）产能项目概述 公司于 2021 年 8 月 20 日召开了第二届董事会第三次会议，审议通过《关于 子公司常熟纳微生物科技有限公司拟购买土地使用权建设生物医药分离纯化用层 析介质研发车间、服务平台及配套设施项目的议案》（以下简称"产能建设项 目"）。 2021 年 12 月 25 日，公司召开了第二届董事会第五次会议，审议通过《关于 ...

证券代码：688690 证券简称：纳微科技 公告编号：2024-080 苏州纳微科技股份有限公司 股东减持股份进展公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 本次减持计划实施前，苏州纳微科技股份有限公司（以下简称"公司"）股 东深圳市纳微科技有限公司（以下简称"深圳纳微"）持有公司股份 78,096,992 股，占公司总股本的 19.3398%，其中无限售条件的流通股 78,096,992 股。 上述股份为公司首次公开发行前取得的股份，并已于 2024 年 6 月 24 日起上 市流通。深圳纳微股东分别为 BIWANG JACK JIANG（中文名：江必旺）博士和陈 荣华先生，其中江必旺博士是公司实际控制人、董事长，持有深圳纳微股权比例 为 77.5973%，陈荣华先生持有深圳纳微股权比例为 22.4027%。 减持计划的进展情况 2024 年 8 月 31 日，公司披露了《苏州纳微科技股份有限公司股东减持股份 计划公告》（公告编号：2024-065），股东陈荣华 ...

Group 1: Company Performance and Market Trends - The company anticipates a recovery in the large molecule filler business due to increasing opportunities in recombinant proteins, vaccines, and blood products, with a focus on domestic market growth [2] - In the small molecule application sector, the GLP-1 drug category has become the fastest-growing area, with increasing domestic insulin market share expected to enhance the replacement opportunities for chromatography fillers [2] - The company is experiencing rapid growth in the small nucleic acid field, with significant project introductions in CDMO and nucleic acid companies [2] Group 2: Product Development and Innovation - The company has increased R&D investment in soft gel products, launching the third-generation Protein A soft gel product, achieving full autonomy in its production and surface functionalization [3] - The new soft gel product, based on proprietary modified alkaline-resistant materials, demonstrates excellent pressure resistance and antibody binding capacity, currently in the market promotion phase [4] - The company has successfully transitioned its agarose production line to formal production, enhancing its soft gel product offerings [4] Group 3: Market Expansion and Competitive Position - The company is actively expanding its overseas market presence, participating in international trade shows, particularly in developing countries, and aims to double its international business [3] - The company has established a strong competitive position in the biopharmaceutical industry, leveraging its advanced microbead preparation technology and comprehensive product array [3] - The company is addressing the increasing competition in the market by enhancing its product offerings and maintaining high customer loyalty [3] Group 4: Financial Management and Shareholder Engagement - The company has initiated a share repurchase plan using 50 million to 100 million yuan of its own funds, with 3.0666 million shares repurchased for a total of 60.9945 million yuan as of November 30, 2024 [4] - The company aims to reduce inventory and accounts receivable as part of its cost reduction and efficiency improvement strategy, addressing cash flow concerns due to increased overdue accounts [4]

关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 苏州纳微科技股份有限公司 重要内容提示： | 回购方案首次披露日 | 2024/1/31，由公司实际控制人、董事长江必旺博 士提议 | | --- | --- | | 回购方案实施期限 | 自董事会审议通过后 12 个月内 | | 预计回购金额 | 万元~10,000 万元 5,000 | | 回购用途 | 用于员工持股计划或股权激励 | | 累计已回购股数 | 306.6622 万股 | | 累计已回购股数占总股本比例 | 0.76% | | 累计已回购金额 | 6,099.45 万元 | | 实际回购价格区间 | 元/股~22.18 元/股 15.52 | 一、 回购股份的基本情况 2024年1月29日，公司召开第二届董事会第三十一次会议，审议通过《关于以 集中竞价交易方式回购公司股份的议案》，同意公司以集中竞价交易方式回购公 司股份，回购资金总额不低于人民币5,000万元（含），不超过人民币10,000万元 （含）；回购价格不超 ...

Commercialization Projects - Commercialization projects accounted for 58% of the semi-annual filler revenue [2] - The proportion of commercialization projects is still relatively low, but it is expected to increase as more projects transition to commercial production [2] - The trend of domestic substitution is strengthening, and the proportion of domestic fillers will continue to rise [2] Filler Replacement Cycle - The replacement cycle for fillers in large-scale commercial production varies depending on customer production conditions, frequency, and the specific performance of the filler [2] - Different steps in the production process may require different replacement cycles for fillers [2] - The company focuses on product iteration and innovation while providing technical services for existing projects [2] Market and Product Development - The company, as a leading player in the biopharmaceutical chromatography industry, has a comprehensive product line and extensive application case experience [2] - With the increasing number of commercialization projects, the company is expected to expand its applications further [2]